Automated, scaled, transposon-based production of CAR T cells.

Dominik LockRazieh MonjeziCaroline BrandesStephan BatesSimon LennartzKarin TeppertLeon GehrkeRafailla Karasakalidou-SeidtTeodora LukicMarco SchmeerMartin SchleefNiels WerchauMatthias EyrichMario AssenmacherAndrew KaiserSabrina PrommersbergerThomas SchaserMichael Hudecek

Published in: Journal for immunotherapy of cancer (2022)

We report on the first automated transposon-based manufacturing process for CAR T cells that is ready for formal validation and use in clinical manufacturing campaigns. This process and platform have the potential to facilitate access of patients to CAR T cell therapy and to accelerate scaled, multiplexed manufacturing both in the academic and industry setting.

Keyphrases

cell therapy
high throughput
end stage renal disease
machine learning
deep learning
chronic kidney disease
ejection fraction
newly diagnosed
stem cells
prognostic factors
mesenchymal stem cells
single cell
patient reported outcomes
risk assessment
human health